Gene Therapy Design Using AAV Viral Vectors | BHU Lecture

Translating gene therapy from laboratory research to human clinical trials involves navigating a complex regulatory landscape. Researchers must obtain safety data from multiple animal models to satisfy FDA requirements, secure recombinant DNA approval, and gain institutional review board clearance through ethical and scientific review processes. Additional federal regulatory requirements include presentations to the Recombinant DNA Advisory Committee and FDA. Beyond regulatory hurdles, the process involves intellectual property negotiations between institutions and lawyers, requiring close collaboration between scientists and clinicians to develop appropriate outcome measures. This comprehensive framework ensures patient safety while enabling the advancement of promising gene therapies toward clinical application.

Translating gene therapy to clinical practice follows established protocols adapted from bone marrow transplantation. The process includes mobilizing stem cells from bone marrow into peripheral blood, isolating CD34+ cells achieving >90% purity, ex vivo genetic modification with lentiviral vectors, conditioning regimens preparing recipients for engraftment, and intravenous infusion of modified stem cells. Safety considerations include malignancy risks from vector integration, addressed through pre-enrollment genetic screening and newer conditioning regimens using anti-CD45 antibodies. Regulatory pathways require extensive preclinical data including toxicity studies and multiple efficacy demonstrations before human trials can proceed.

This extensive section traces the complete journey from laboratory discovery to potential patient treatment. It covers the sequential phases of drug development: preclinical studies in animals and cell cultures establishing safety and dosing parameters; IND application filing with regulatory agencies; Phase 1/2 studies assessing safety and initial efficacy in disease populations (typically skipping healthy volunteers due to manufacturing costs); Phase 3 studies as larger randomized trials with control groups providing approval data; and Phase 4 studies monitoring long-term outcomes post-approval. The section emphasizes that clinical trials are scientific experiments designed to test safety and efficacy, not clinical care, requiring strict protocol adherence and careful consideration of risks and benefits.

The FDA's 2013 guidance establishes a science-driven framework for preclinical assessment of cell and gene therapy products. Key objectives include supporting first-in-human study design through proof-of-concept studies, demonstrating safety through comprehensive toxicology testing, determining adequate dosing plans, and informing clinical trial design including starting doses and escalation schemes. The framework incorporates the 3Rs principle (reduce, refine, replace animal use) and emphasizes product-specific testing strategies while maintaining basic toxicology principles.

Clinical trial regulations were established after the talidomide tragedy in the 1950s-1960s, which caused severe birth defects in fetuses of pregnant women taking the sedative. This event led to modern standards requiring all medications to prove both effectiveness and safety through clinical trials. The drug development process begins with laboratory research where scientists identify biological targets and test tens of thousands of molecules, with over 90% failing to advance. Preclinical research on cell and animal models precedes human testing. Clinical trials consist of four phases: Phase 1 (10-50 participants) focuses on safety and dosing; Phase 2 (100-300 participants) confirms effectiveness; Phase 3 (thousands of participants) compares to standard treatments; Phase 4 studies in broader populations after approval. Trials require approval from regulatory agencies and independent ethics committees. Ethics committees must be independent from sponsors, researchers, and institutions to avoid conflicts of interest. They include representatives from law, medicine, ethics, and patients. This multi-layered oversight ensures trials are scientifically sound, ethically conducted, and protect participant rights and safety.

Viral delivery systems like AAV leverage millions of years of evolutionary optimization for efficient intracellular delivery but face significant limitations: immunogenicity triggering immune responses, tolerability challenges requiring large systemic doses, and inability to repeat dosing. Non-viral lipid nanoparticles avoid immunogenicity but struggle with systemic delivery to extravascular targets like tumors. The key insight is that conventional LNPs rely on endosomal escape mechanisms that trigger immune detection pathways. This comparison establishes the motivation for developing hybrid approaches that combine the best aspects of both worlds while overcoming their individual limitations.

Lentiviruses serve as powerful tools for gene delivery and therapy due to several key advantages: (1) Stable integration into the host cell genome ensures long-term expression for generating stable cell lines; (2) They can infect both dividing and non-dividing cells such as hepatocytes and neurons, which are notoriously difficult to infect with other viral vectors; (3) Broad tropism makes them effective vehicles for delivering CRISPR sgRNA constructs to edit genes within any tissue type; (4) They do not generate immunogenic proteins; (5) They can deliver transgene fragments as large as 9 kilobases.

Gene delivery platforms differ significantly in mechanism, efficiency, and application suitability. Electroporation achieves high delivery efficiencies through electrical pulse-induced membrane permeabilization, while lipid nanoparticles (LNPs) offer non-invasive delivery through natural cellular uptake pathways. LNPs provide advantages in avoiding electric field-induced cell damage and enable scalable manufacturing suitable for commercial vaccine production. Both platforms require optimization for specific cell types and therapeutic applications. The choice between them depends on factors including cell viability requirements, manufacturing scalability needs, and target tissue specificity considerations.

Nucleic acid delivery uses viral and nonviral vectors. Viral vectors use viral glycoproteins for high transfection efficiency but face safety concerns including immunogenicity and carcinogenicity. Nonviral vectors include lipid nanoparticles (LNPs), liposomes, polymeric carriers (PLGA, dendrimers), and bioengineered systems (exosomes, VLPs). Nonviral systems offer better biocompatibility, lower immunogenicity, and higher packaging capacity (12-22 KB vs 5-8 KB for viral). The mRNA COVID-19 vaccine demonstrates nonviral vector efficacy.

Viral vectors are essential vehicles for gene therapy, with pathogenic properties eliminated to focus on gene insertion. Adenovirus carries double-stranded DNA with a 32-36 hour infection cycle but has low cellular specificity and triggers immune responses. Retroviruses integrate permanently into host chromosomes, transferring genes to all daughter cells, but pose safety risks from random integration. Lentiviruses establish latency in cells, limiting their effectiveness in immune-compromised patients. Non-viral systems like liposomes offer easier production and reduced immune response risks. Liposomes are phospholipid polymers functioning as cellular targeting 'antennas' with 3-2500 molecules. Naked DNA injection requires careful dosage consideration. Artificial chromosomes replicate once per cell cycle and carry large genetic payloads. Cationic liposomes carry positive charges for cellular membrane interaction. Hybrid methods like virosomes combine liposomes with inactivated viruses. Dendrimers are hyperbranched macromolecules with central cores, branching units, and terminal groups, synthesized through cascade processes.

Base editing enables direct conversion of individual nucleotides without double-strand breaks by fusing Cas9 to deaminase enzymes (APOBEC or ADAR), converting C→U or A→G. Prime editing combines Cas9 with reverse transcriptase to enable precise insertions, deletions, and substitutions using prime editing guide RNAs that encode both target sequences and desired edits. CRISPR can also deliver epigenetic modifiers—dCas9 fused to VP64 activators, p300 histone acetyltransferases, or DNA methyltransferases—to regulate gene expression at specific promoters or enhancers without altering DNA sequence.

Beyond DNA cutting, CRISPR enables precise single-nucleotide modifications through base editing. Dead Cas9 fused to cytosine or adenine deaminases converts specific bases without double-stranded breaks, achieving over 50% efficiency for corrections. Alternative Cas proteins like Cpf1 expand targeting flexibility with different PAM requirements. Dead Cas9 variants enable epigenetic regulation by delivering transcription factors, repressors, or modifiers to specific genomic loci. These advances allow temporal and spatial control of gene expression patterns, representing the frontier of genome engineering capabilities.

Second-generation base editors combine dead Cas9 with deaminase enzymes to chemically convert specific nucleotides (C→T or A→G) without cutting DNA strands, eliminating genetic noise while enabling precise single-letter corrections. Third-generation prime editors combine Cas9 with reverse transcriptase to enable insertions, deletions, and substitutions without double-strand breaks. Prime editing achieves similar correction rates to first-generation CRISPR but with dramatically reduced mosaicism. These technologies have entered clinical trials, with the first prime editing clinical trial beginning in May 2024. Applications include treating phenylketonuria, tyrosinemia type I, retinitis pigmentosa, progeria, hypertrophic cardiomyopathy, and chronic granulomatous disease. Avatar mouse models carry exact human mutations, enabling preclinical testing of potential treatments and helping clarify pathogenicity of variants of uncertain significance.

This section covers advanced CRISPR technologies. Base editors are CRISPR-based systems that make precise point mutations without creating double-strand breaks. They consist of Cas9 nickase fused to cytidine or adenine deaminase enzymes. The system recognizes the target sequence and deaminates the target base (C to U or A to G), which is then converted to T or G during DNA replication. This allows correction of point mutations but has limitations: can only edit specific base pairs, and efficiency depends on local sequence context. Prime editors are next-generation systems that can make any type of point mutation, insertions, and deletions. They consist of Cas9 nickase fused to reverse transcriptase and a specially designed guide RNA with a primer binding site. The system creates a single-strand break and uses the guide RNA as a template to synthesize the desired edit. Prime editors can insert up to 44 base pairs and make any type of point mutation, overcoming many limitations of base editors and traditional CRISPR systems.

CRISPR-Cas systems have been adapted for base editing and prime editing: (1) Base editing uses Cas9 fused to a cytidine deaminase or adenine deaminase to convert specific bases without DNA cleavage; (2) Prime editing uses Cas9 fused to a reverse transcriptase and a prime editing guide RNA to insert, delete, or replace specific DNA sequences. CRISPR-Cas systems can also be used for epigenetic editing by fusing Cas proteins to epigenetic modifiers like DNA methyltransferases or histone modifiers, enabling precise control of gene expression without changing the DNA sequence.